Advertisement
Advertisement
U.S. Markets close in 6 hrs 30 mins
Advertisement
Advertisement
Advertisement
Advertisement

Regencell Bioscience Holdings Limited (RGC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
20.84-4.07 (-16.34%)
As of 04:00PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.91
Open23.80
Bid18.81 x 800
Ask20.00 x 1000
Day's Range20.75 - 20.75
52 Week Range6.00 - 59.00
Volume117
Avg. Volume127,204
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO

    HONG KONG, November 22, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that Yat-Gai Au, the Company’s Chairman & CEO, made Ordinary Share purchases of Regencell ("Ordinary Shares") totaling $1,125,807.

  • Business Wire

    Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index

    HONG KONG, November 22, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that the ordinary shares of the Company will be added to the MSCI World Micro Cap Index on November 30, 2021 after the close of market (effective

  • Zacks Small Cap Research

    RGC: Traditional Chinese Medicine Approach for treatment of neurodevelopmental conditions

    By Beth Senko, CFA NASDAQ:RGC Founded in 2014, Hong Kong-based Regencell Bioscience (NASDAQ:RGC) is an early clinical stage bioscience company using a traditional Chinese medicine (TCM) approach to develop standardized TCM formulas to holistically treat different elements of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in adolescents, and infectious diseases

Advertisement
Advertisement